Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05003141




Registration number
NCT05003141
Ethics application status
Date submitted
20/07/2021
Date registered
12/08/2021
Date last updated
28/03/2022

Titles & IDs
Public title
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Scientific title
A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Secondary ID [1] 0 0
PSB202-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma 0 0
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 0 0
Waldenstrom Macroglobulinemia 0 0
Marginal Zone Lymphoma 0 0
Mantle Cell Lymphoma 0 0
Indolent Lymphoma 0 0
Refractory B-Cell Lymphoma 0 0
MALT Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PSB202

Experimental: Single-arm, escalating dose levels - 3 + 3 Phase 1 dose escalation design; sequential ascending dose levels.


Treatment: Drugs: PSB202
PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse Events
Timepoint [1] 0 0
Through study completion; up to 27 weeks
Primary outcome [2] 0 0
Dose Limiting Toxicity (DLT)
Timepoint [2] 0 0
3 weeks
Secondary outcome [1] 0 0
Peak Plasma Concentration (Cmax)
Timepoint [1] 0 0
2 months
Secondary outcome [2] 0 0
Area under the Plasma Concentration versus Time Curve (AUC)
Timepoint [2] 0 0
2 months
Secondary outcome [3] 0 0
Number of Patients with measurable Anti-Lymphoma Response
Timepoint [3] 0 0
Up to 27 weeks
Secondary outcome [4] 0 0
Change in CD20+ cell counts
Timepoint [4] 0 0
2 months

Eligibility
Key inclusion criteria
Phase 1a (dose escalation):

1. Histologically confirmed CD20+ expressing indolent NHL (defined below), CLL or WM,
failed or intolerant to standard of care therapies;

2. Relapsed/refractory following at least 2 prior lines of standard of care treatment.
Prior treatments received must be documented on the enrollment request form. For FL,
prior treatment must have included at least 1 rituximab containing regimen.

3. First three dose levels: in the opinion of the investigator, able to tolerate
potentially subtherapeutic doses of PSB202 for the duration of a 28-day DLT
observation window.

Phase 1b - Dose Expansion:

4. Histologically confirmed CD20+ expression. For CD37+, if unavailable from the chart at
screening, CD37+ expression may be documented from a new or archived blood specimen
after enrollment.

5. Relapsed indolent NHL: histologies that may be included are CLL/SLL, MZL,
MALT-lymphoma, follicular NHL, MCL or WM failed, relapsed/refractory or intolerant to
at least 2 standard of care therapies. (APPENDIX B). For FL, prior treatment must have
included rituximab. MCL must have received a prior alkylating agent.

6. Patients must have documented disease progression after at least two prior
standard-of-care regimens.

7. Patients must have measurable disease.

All Patients:

8. Signed Informed Consent;

9. Eastern Cooperative Oncology Group (ECOG) 0-2

10. Last dose of any anti-CD20 antibody therapy must have been >4 weeks before the first
dose of PSB202

11. Patients with a medical history of Covid-19 positivity at within 6 months prior to
enrollment, must be retested within 7 days of enrollment and confirm Covid-19
negativity by a PCR-test.

12. At least 18 years of age. There is no upper age restriction.

13. Four weeks wash-out from any other prior cancer therapy, including rituximab or
BTK-inhibitors. However, some heavily pretreated patients are at risk for significant
morbidity from accelerated disease progression or "flare" when treatment is
discontinued prior to the initiation of subsequent effective therapy. Absent residual
toxicity and with documented Medical Monitor approval, such patients may receive study
drug after five drug half-lives have passed following discontinuation of the immediate
pre-study therapy.

14. Adequate hematologic and coagulation status, defined as the following on C1D1 before
treatment:

1. Absolute neutrophil count (ANC) = 0.75 billion/L; not requiring growth factors;
after the DLT period, growth factor support is allowed and considered supportive
care.

2. Platelet count =75 billion/L not requiring transfusion support; if there is
documented bone marrow involvement, platelet transfusions may be used up to 7
days prior to C1D1 to achieve this threshold.

3. Hemoglobin (Hb) =9 mg/dL not requiring transfusion support or growth factors.
After the DLT period, growth factor support is allowed and considered supportive
care.

4. Adequate coagulation, defined as aPTT and PT (INR) not greater than 1.5 × upper
limit of normal (ULN) (patients appropriately anticoagulated for a preexisting
medical condition [e.g., atrial fibrillation] may be eligible with documented
Sponsor approval).

15. Adequate hepatic function, defined as:

1. ALT or AST =2.5 X the ULN or =5 X ULN with documented liver involvement.

2. Total bilirubin =1.5 X ULN or =3 X ULN with documented liver involvement and/or
Gilbert's Disease

3. Adequate renal function, with estimated glomerular filtration rate (eGFR) =50
mL/minute.

16. Ability to comply with outpatient treatment, laboratory monitoring, and required
clinic visits for the duration of study participation.

17. Willingness of men and women of reproductive potential to observe conventional and
effective birth control for the duration of treatment and for 3 months following the
last dose of study treatment; this may include barrier methods such as condom or
diaphragm with spermicidal gel.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

Phase 1a (dose escalation) only:

18. NHL with bulky disease defined as a mass =10 cm in longest diameter

19. Transformation (e.g., Richter's transformation, prolymphocytic leukemia, transformed
NHL, blastoid lymphoma) prior to planned start of PSB202. In addition, no concurrent
investigational therapy is permitted.

All patients: Phase 1a (dose escalation) and Phase 1b (dose expansion):

20. Major surgery within 4 weeks prior to planned start of PSB202

21. Radiotherapy with a limited field of radiation for palliation within 7 days of the
first dose of study treatment, except for patients receiving radiation to more than
30% of the bone marrow or receiving whole brain radiotherapy, which must be completed
at least 4 weeks prior to the first dose of study treatment

22. Continuation of certain standard of care anticancer therapies, including hormonal
therapy for breast and prostate cancer, and growth factor support after completion of
the DLT-period, is allowed.

23. Therapeutic monoclonal antibody treatment must be discontinued a minimum of 4 weeks
prior to the first dose of PSB202. PSB202 may be started sooner after prior
investigational agent or anticancer therapy if considered by the Investigator to be
safe and within the best interest of the patient (e.g., to avoid disease flare) and
with documented Sponsor approval.

24. Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2
or greater at the time of starting study treatment except for alopecia.

25. History of autologous stem cell transplant (auto-SCT) or chimeric antigen
receptor-modified T cell (CAR-T) therapy within the past 180 days with any of the
following: cytopenias from incomplete blood cell count recovery post-transplant, need
for anti-cytokine therapy, residual symptoms of neurotoxicity > Grade 1, or ongoing
immunosuppressive therapy.

26. Active graft versus host disease (GVHD, including resultant from any prior solid organ
transplants, if received), or ongoing immunosuppressive therapy.

27. History of allogeneic stem cell transplant (allo-SCT) or allogeneic CAR-T at any time
in the patient's medical history

28. Known central nervous system (CNS) involvement by lymphoma. Patients with previous
treatment for CNS involvement who are neurologically stable and without evidence of
active CNS-disease may be eligible if a clinical rationale is provided by the
Investigator and with documented Sponsor approval

29. Active auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic
thrombocytopenic purpura [ITP])

30. Cerebrovascular accident (CVA), Transient ischemic attack (TIA), myocardial
infarction, unstable angina, or New York Heart Association (NYHA) class III or IV
heart failure < 6 months of study screening; mean ECG QT-interval corrected according
to Fridericia's formula (QTcF) > 450 milliseconds (ms) (males) or > 470 ms (females)
obtained from three ECGs; uncontrolled arrhythmia < 3 months of study screening.
Patients with rate-controlled arrhythmias may be eligible for study entry at
discretion of the Investigator.

31. Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except
for fungal nail infection), or other clinically significant active disease process
which in the opinion of the Investigator and the Sponsor makes it undesirable for the
patient to participate in the trial. Screening for chronic conditions is not required.

32. Tested positive for Human Immunodeficiency Virus (HIV) is excluded (due to potential
drug-drug interactions between anti-retroviral medications and PSB202 and risk of
opportunistic infections). For patients with unknown HIV status, HIV testing will be
performed at Screening

33. Active viral hepatitis (B or C, HBsAg, anti-HBs/HBcAb and anti-HCV Ab tests) as
demonstrated by positive serology or requiring treatment. Subjects who are
anti-HBs/HBcAb (+) without detectable HBV-DNA are eligible. Subjects with a history of
Hepatitis C and have received successful curative treatment are eligible.

34. Pregnancy or lactation.

35. Active autoimmune disease or history of autoimmune disease requiring systemic therapy
< 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease,
Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that
has not been active in the 2 years prior to study screening are eligible.

36. History of drug-induced liver injury or cirrhosis

37. History of pneumonitis or interstitial lung disease

38. Patients with significant medical diseases or conditions, as assessed by the
Investigator and Sponsor, that would substantially increase the risk-benefit ratio of
participating in the study.

-

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2024
Actual
Sample size
Target
110
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Epworth Healthcare - East Melbourne
Recruitment hospital [2] 0 0
One Clinical research - Perth
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
6153 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Kentucky
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
China
State/province [3] 0 0
Shanghai

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal
antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized
anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single
product with the two components of PSB202 enabling a distinct dual target-specific antibody
directed cell killing of B-cells.

Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with
indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study
follows a 3+3 design.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05003141
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lindsey E. Roeker, MD
Address 0 0
Memorial Sloan-Kettering Cancer Center, New York, NY
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Jelle W. Kijlstra, MD
Address 0 0
Country 0 0
Phone 0 0
2069091125
Fax 0 0
Email 0 0
jelle@soundbiologics.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05003141